The Growth of the Sample Preparation Market

Thursday, March 23, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, March 23, 2017 /PRNewswire/ --

A research report by Mordor

Intelligence indicates that the global sample preparation market is expected to reach USD 7.2 billion by the end of 2021 and growing at a CAGR of 7.1%. Sample preparation is a procedure in which a sample is preserved prior
to its analysis. Preparation is a crucial step in most analytical procedures since the methods are often allowing repeated testing. The report explains that the sample preparation is one of the most shared procedures in the lab. In many life science labs, it can devour most of the lab's capacity, and often encompasses a number of physical error-prone steps. Pressure BioSciences, Inc. (OTC: PBIO), Danaher Corporation (NYSE: DHR), Hologic, Inc. (NASDAQ: HOLX), Koninklijke Philips NV (NYSE: PHG), Illumina, Inc. (NASDAQ: ILMN)

The sample preparation market is segment of the medical devices market. Grace Market Data projects that the global medical devices (MD) market will see a steady growth over the coming years with the sales revenue and international trade value reaching $543.9 billion and $289.2 billion respectively by 2020, which is driven by the aging population, increasing healthcare expenditure and technology advancement. Medical devices are the equipment, instruments used in medical industries by professional surgeons, medical assistants and doctors for healthcare of patients. Companies in this industry manufacture medical devices, surgical equipment and appliances.

Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide.

Just yesterday Pressure BioSciences announced financial results for the fourth quarter and fiscal year ended December 31, 2016. The company stated, "55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016. New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017."

Richard T. Schumacher, President and CEO of PBI, commented: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017. These accomplishments have let us enter the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; important additions to our hard-working and talented staff; a larger customer base; and an expanded and enhanced sales and marketing capability."

Mr. Schumacher continued: "Our near-term goals are clear, focused, and attainable in 2017. We believe their achievement will subsequently position PBI to be a stronger, more valuable company. These goals include: (i) an up-list to the NASDAQ stock market in Q2 2017, (ii) measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity, (iii) continuation of the current expansion of our sales and marketing capabilities, and our reach into new countries, investigators, and fields-of-use; and (iv) a focus on sales, sales, and sales."

Danaher Corporation (NYSE: DHR) designs, manufactures and markets professional, medical, industrial and commercial products and services. With more than 20 operating companies, Danaher's globally diverse team of over 62,000 associates is united by a common culture and operating system, the Danaher Business System. Pressure BioSciences, previously announced an exclusive co-marketing agreement with SCIEX, a company focuses on science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation. Under the agreement, the companies will jointly promote Pressure BioSciences' PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation.

Hologic, Inc. (NASDAQ: HOLX) is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. The company recently announced that it has completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies.

Koninklijke Philips NV (NYSE: PHG) is a health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, and Lighting. The Company's Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. Recently Philips that the results from two large clinical trials comparing patient outcomes using instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the diagnosis and treatment of heart disease have been published in the New England Journal of Medicine. First released in 2013, iFR is an innovative pressure-derived index unique to Philips, a global leader in image-guided therapy solutions, allowing hyperemia-free physiological assessment of coronary blockages.

Illumina, Inc. (NASDAQ: ILMN) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). On March 21st it was announced that Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich™ line of research solutions for pharmacogenetics targets through its commercial channels.

Please Sign Up Now at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated a total of ten thousand dollars for financial news dissemination and pr services by pressure biosciences, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store